Genome Interpretation, Nanoparticles, Gene Therapy, 2024 IPOs; Nautilus Biotechnology

Episode 7 (February 2, 2024): Simplify Genomics launches genome interpretation platform, COUR’s nanoparticles for autoimmunity, gene replacement therapy for heart condition, CG Oncology and ArriVent IPOs; an interview with Nautilus Biotechnology co-founders, Sujal Patel and Parag Mallick.Listed below are key references to the GEN stories, media and other items discussed in this episode of Touching Base:Human Longevity Spin-Out Aims to Tap into Variant Interpretation MarketBy Uduak Thomas, GEN, January 31st, 2024Light My Fire: COUR Raises $105M Series A to Advance Tolerogenic Nanoparticles for AutoimmunityBy Jonathan Grinstein, GEN Edge, January 30th, 2024 Gene Replacement Therapy Halts Fatal Arrhythmogenic Condition in MiceGEN, January 30th, 2024 StockWatch: IPO Revival? CG Oncology, ArriVent Raise a Combined $555MBy Alex Philippidis, GEN Edge, January 28th, 2024       Hosted on Acast. See acast.com/privacy for more information.